1. Home
  2. LQDA vs ADAMI Comparison

LQDA vs ADAMI Comparison

Compare LQDA & ADAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • ADAMI
  • Stock Information
  • Founded
  • LQDA 2004
  • ADAMI N/A
  • Country
  • LQDA United States
  • ADAMI United States
  • Employees
  • LQDA N/A
  • ADAMI N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • ADAMI Real Estate Investment Trusts
  • Sector
  • LQDA Health Care
  • ADAMI Real Estate
  • Exchange
  • LQDA Nasdaq
  • ADAMI Nasdaq
  • Market Cap
  • LQDA 2.5B
  • ADAMI 2.3B
  • IPO Year
  • LQDA 2018
  • ADAMI N/A
  • Fundamental
  • Price
  • LQDA $25.00
  • ADAMI $24.90
  • Analyst Decision
  • LQDA Strong Buy
  • ADAMI
  • Analyst Count
  • LQDA 9
  • ADAMI 0
  • Target Price
  • LQDA $32.11
  • ADAMI N/A
  • AVG Volume (30 Days)
  • LQDA 2.2M
  • ADAMI N/A
  • Earning Date
  • LQDA 11-12-2025
  • ADAMI N/A
  • Dividend Yield
  • LQDA N/A
  • ADAMI N/A
  • EPS Growth
  • LQDA N/A
  • ADAMI N/A
  • EPS
  • LQDA N/A
  • ADAMI N/A
  • Revenue
  • LQDA $19,322,000.00
  • ADAMI N/A
  • Revenue This Year
  • LQDA $405.58
  • ADAMI N/A
  • Revenue Next Year
  • LQDA $373.93
  • ADAMI N/A
  • P/E Ratio
  • LQDA N/A
  • ADAMI N/A
  • Revenue Growth
  • LQDA 30.20
  • ADAMI N/A
  • 52 Week Low
  • LQDA $9.68
  • ADAMI N/A
  • 52 Week High
  • LQDA $29.94
  • ADAMI N/A
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.82
  • ADAMI N/A
  • Support Level
  • LQDA $25.34
  • ADAMI N/A
  • Resistance Level
  • LQDA $28.00
  • ADAMI N/A
  • Average True Range (ATR)
  • LQDA 1.32
  • ADAMI 0.00
  • MACD
  • LQDA -0.70
  • ADAMI 0.00
  • Stochastic Oscillator
  • LQDA 0.50
  • ADAMI 0.00

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: